perifosine has been researched along with ruboxistaurin in 1 studies
| Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) |
|---|---|---|---|---|---|
| 245 | 31 | 140 | 203 | 29 | 56 |
| Protein | Taxonomy | perifosine (IC50) | ruboxistaurin (IC50) |
|---|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.6484 | |
| Protein kinase C gamma type | Homo sapiens (human) | 0.3 | |
| Protein kinase C alpha type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Homo sapiens (human) | 0.0054 | |
| Protein kinase C delta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C zeta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.2 | |
| Protein kinase C alpha type | Homo sapiens (human) | 0.36 | |
| Protein kinase C eta type | Homo sapiens (human) | 0.052 | |
| Protein kinase C gamma type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C beta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Protein kinase C epsilon type | Homo sapiens (human) | 0.6 | |
| Protein kinase C delta type | Homo sapiens (human) | 0.25 | |
| Protein kinase C eta type | Rattus norvegicus (Norway rat) | 0.32 | |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
| Protein kinase C theta type | Rattus norvegicus (Norway rat) | 0.32 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
1 other study(ies) available for perifosine and ruboxistaurin
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |